Anzeige
Erschienen in:
01.11.2007 | Brief Communication
The incidence of aberrant endometrial αvβ3 vitronectin expression in a high risk infertility population: could prolonged GnRH agonist therapy play a role?
Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 11/2007
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Evaluate the incidence of aberrant endometrial integrin (αvβ3 vitronectin) expression in patients at high risk for implantation defects.
Materials and methods
Retrospective case-control trial of 74 consecutive infertile patients with prior failed IVF cycles despite good embryo quality and/or endometriosis who underwent endometrial biopsy 9–11 days after an LH surge to assess the presence or absence of αvβ3 vitronectin. Patients were separated into two groups for analysis based on the presence (Gr. A) or absence (Gr. B) of integrin expression. A subset of Gr. B patients (86.1%) was treated with a 2 month course of a GnRH agonist prior to IVF (Gr. B1). No Gr. A patients were so treated.
Results
Absent αvβ3 vitronectin expression was noted in 48.6% of patients evaluated. A trend towards more severe endometriosis was noted in Gr. B (57.1 vs 31.5%). Responses to controlled ovarian hyperstimulation and IVF cycle outcomes including ongoing pregnancy rates were similar between Gr. B1 patients untreated Gr. A controls (55.6 vs 63.9%).
Conclusions
A high incidence of absent endometrial αvβ3 vitronectin expression is noted in patients at increased risk for implantation defects. Prolonged GnRH agonist therapy prior to an IVF cycle resulted in outcomes similar to untreated controls with positive expression.